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Abstract
Using bioinformatics, we have identified a novel tumor-
specific gene BJ-TSA-9, which has been validated by
Northern blot analysis and reverse transcription–
polymerase chain reaction (RT-PCR). BJ-TSA-9 mRNA
was expressed in 52.5% (21 of 40) of human lung cancer
tissues and was especially higher in lung adeno-
carcinoma (68.8%). To explore the potential applica-
tion of BJ-TSA-9 for the detection of circulating cancer
cells in lung cancer patients, nested RT-PCR was
performed. The overall positive detection rate was
34.3% (24 of 70) in peripheral blood mononuclear cells
(PBMCs) of patients with various types of lung cancers
and was 53.6% (15 of 28) in PBMCs of lung adenocarci-
noma patients. In combination with the detection of two
known marker genes SCC and LUNX, the detection rate
was increased to 81.4%. A follow-up study was per-
formed in 37 patients after surgical removal of tumor
mass. Among nine patients with persistent detection
of two to three tumor marker transcripts in PBMCs, six
patients had recurrence/metastasis. In contrast, 28 pa-
tients with transient detection of one tumor marker or
without detection of any tumor marker were all in re-
mission. Thus, BJ-TSA-9may serve as a marker for lung
cancer diagnosis and as a marker, in combination with
two other tumor markers, for the prediction of the
recurrence and prognosis of lung cancer patients.
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Introduction
Lung cancer is the leading cause of cancer-related deaths
worldwide. In all developed countries and many developing
countries, the 5-year survival rates for lung cancer are less
than 15% and 5%, respectively [1]. Despite some advances
in early detection,more radical surgical treatments, andmulti-
modal therapeutic strategies over the last decade, the prog-
nosis of patients with lung cancer remains relatively poor.
Nearly 50% of early-stage lung cancer patients will relapse
or develop distant metastases within 5 years after surgical
removal of tumor mass. This fact suggests the existence of
occult metastatic cells, which are undetectable by current
methods [2]. The spread of cancer cells by the hematogenous
route is important in lung cancer metastasis. Thus, development
of sensitive and specific detectionmethods for circulating cancer
cells in the peripheral blood may have important diagnostic,
prognostic, and therapeutic implications [3].
Conventional immunohistochemistry and pathology are rel-
atively insensitive to the detection of occult cancer cells in
peripheral blood samples. Several research groups, including
our group, have reported the use of reverse transcription–
polymerase chain reaction (RT-PCR) to detect disseminated
tumor cells in the peripheral blood [4–7]. This assay, which is
currently believed to be themost sensitive means for identifying
circulating tumor cells [8,9] and has been applied in the diag-
nosis of malignant melanomas [10–12], colon cancers [13],
breast cancers [14–16], neuroblastomas [17], thyroid cancers
[18], and hepatocellular carcinomas [6,19,20], is able to detect
a single tumor cell present in the peripheral blood. As for lung
cancer, several marker genes, such as preproGRP, cytokeratin,
and carcinoembryonic antigen (CEA), have been employed to
detect tumor cells dispersed in the circulation [21–23]. However,
most of these known transcripts displayed significant levels
of illegitimate transcription in peripheral blood samples taken
from healthy volunteers [24–26]. It is hence desirable to have
markers expressed in embryonic or cancerous tissues, but not
in adult normal human tissues.
We have recently identified a novel tumor-specific gene
BJ-TSA-9, which is highly expressed in lung cancer tissues. By
nested RT-PCR, BJ-TSA-9 was detected in peripheral blood
mononuclear cell (PBMC) samples from lung cancer patients,
indicating the presence of circulating cancer cells. We have
also chosen twoknown tumormarker genes, squamouscell car-
cinoma antigen (SCC) and lung-specific X protein (LUNX), for
detecting circulating lung cancer cells. SCC is a purified sub-
fraction of tumor antigen TA-4 obtained from squamous cell
Abbreviations: CEA, carcinoembryonic antigen; G3PDH, glyceraldehyde-3-phosphate dehy-
drogenase; HERV, human endogenous retrovirus; ORF, open reading frame; PBMC,
peripheral blood mononuclear cell; SCC, squamous cell carcinoma antigen
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cancer tissues of the uterine cervix [27], which is also
expressed at high concentrations in various neoplasias de-
rived from squamous cells [28] and has been applied as a
tumor marker of lung cancer [29]. LUNX is a lung-specific
gene whose mRNA expression is strictly limited to lung tis-
sues and has been reported to be a sensitive marker for
lung cancer [30,31]. With the combination of BJ-TSA-9
with SCC and LUNX, the detection rate of circulating tumor
cells was markedly increased, and such detection was cor-
related with the clinical outcome of lung cancer patients.
Thus, BJ-TSA-9 appears to be a promising tumor biomarker
of lung cancer.
Materials and Methods
Tumor Specimens
All samples from cancer patients were collected with
written consents and were approved by the Hospital Ethics
Review Committee. Clinical diagnosis was confirmed by
pathological examination. Tumor stages and grades were
classified according to the fifth edition of the Tumor–Node–
Metastasis classification of the International Union Against
Cancer. Samples of human lung cancer tissues and paired
noncancerous tissues (5 cm away from the tumor) were ob-
tained during surgical resection from the Peking University
First Hospital. The resected tissue samples were immedi-
ately cut into small pieces and snap frozen in liquid nitrogen
until use.
Blood Samples
Venous blood samples from lung cancer patients (n = 70)
were collected preoperatively by standard transcutane-
ous needle venipuncture and placed into citrate sodium–
containing tubes. Blood was collected into two tubes, with
1 ml in the first tube and 5 ml in the second tube. The blood in
the first tube, which may have been contaminated with epi-
thelial cells picked up by the needle when it pierced the skin,
was discarded, whereas the blood in the second tube was
used for RNA preparation. The blood samples were also
collected from healthy donors (n = 20). The blood was placed
on a Ficoll-Hypaque layer (Gibco BRL, Grand Island, NY),
and the PBMCs were collected after density gradient centri-
fugation. The collected cells were washed twice with sterile
phosphate buffer solution. Cell pellets were then snap frozen
and stored at 80jC until RNA extraction.
Cell Lines
BJ-TSA-9 transcript was detected by RT-PCR in the fol-
lowing tumor cell lines: A549 and PAa (lung adenocarci-
noma); Bel-7402, Bel-7405, HLE, and HepG2 (hepatocellular
carcinoma); Jurkat (leukemia); and Mel-kenny (melanoma).
These cell lines were maintained in DMEM (Gibco BRL)
mediumcontaining 10% fetal calf serum (Hyclone, Logan,UT).
cDNA samples from eight tumor cell lines of melanoma,
lung, breast, pancreas, colon, prostate, and ovary cell lines
were purchased from Clontech Laboratories, Inc. (Palo Alto,
CA) and enrolled in this study.
RNA Preparation and cDNA Synthesis
Total RNA was extracted from cancer tissues and cell
lines using Trizol (Gibco BRL) reagent, according to the pro-
tocol provided by the manufacturer. Total RNA was checked
by agarose gel electrophoresis for ribosomal RNA integrity,
and RNA quantity was measured by an ultraviolet spectrom-
eter. Total RNA (2 mg) was primed with an oligo-(dT)15 oligo-
nucleotide (Promega, Madison, WI) and reverse-transcribed
into cDNA using advantage reverse transcriptase (Clontech
Laboratories, Inc.), according to the protocol provided by
the manufacturer.
mRNA expression pattern in human normal tissues was
assessed by RT-PCR, using a panel of commercially avail-
able cDNA (Clontech Laboratories, Inc.). The panel is com-
posed of cDNA generated from RNA isolated from 16 human
normal tissues: brain, heart, kidney, liver, lung, pancreas, pla-
centa, skeletal muscle, colon, ovary, peripheral blood leuko-
cyte, prostate, small intestine, spleen, testis, and thymus.
Northern Blot Analysis
Northern blot analysis was performed with total RNA
samples extracted from lung cancer tissues and paired non-
cancerous tissues. RNA integrity was examined by electro-
phoresis in formalin/4-morpholine propane sulfuric acid gels.
Twenty micrograms of total RNA per lane was first separated
by electrophoresis in 1.2% agarose containing 3% formal-
dehyde and then blotted onto Hybond-C nylon membranes
(Amersham, Piscataway, NJ). The membrane was cross-
linked by ultraviolet radiation. DIG-labeled probes spanned
the full length of the open reading frame (ORF) sequence
(1101 bp) of BJ-TSA-9. After prehybridization, the mem-
brane was hybridized overnight to specific DIG-labeled
probes at 42jC in hybridization solution (50% formamide,
5 SSC, 0.1% N-lauroylsarcosine, 0.02% SDS, 2% blocking
reagent, and 100 mg/ml sheared salmon sperm DNA). The
hybridized filter was then sequentially washed at room
temperature for 30 minutes in 0.1% SDS at 2 SDS, and
at 68jC for 30 minutes in 0.1% SDS and 0.1 SDS. After
stringent washes, the corresponding mRNA in Northern blot
analysis was detected by chemiluminescence using CSPD
ready-to-use reagent (Roche, Indianapolis, IN).
RT-PCR Analysis
Sequences of primers for target genes are listed in
Table 1. Sample cDNA (2.5 ml) was 10-fold diluted with a
PCR mixture containing 0.1 mmol per primer pair, 0.2 mM de-
oxynucleotide triphosphate, 50 mMTris–HCl (pH 8.3), 10 mM
KCl, 5 mM(NH4)2SO4, 2 mM MgCl2, and 0.75 U of Taq DNA
polymerase (Tianwei, Beijing, China) in a total volume of 25 ml.
PCR was performed using GeneAmp PCR system 9700
(Applied Biosystems, Foster City, CA). For cancer tissues
and cancer cell lines, RT-PCR of BJ-TSA-9 was performed
with primers B2 and B4. The parameters were as follows:
35 cycles at 94jC for 20 seconds, at 64jC for 30 seconds,
and at 72jC for 60 seconds, followed by 7 minutes at 72jC.
For peripheral blood samples, the primers of all these
three genes for PCR amplification are listed in Table 1.
Taking 2.5 ml of 10-fold–diluted cDNA as template for the
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first round, PCR conditions were as follows: 35 cycles at
94jC for 20 seconds, at 60jC for 30 seconds, and at 72jC
for 90 seconds, followed by 7 minutes at 72jC. Then 2 ml
of the 1:100–diluted first-round PCR product was used as
template for the second round of the PCR reaction. The
second round was cycled at 94jC for 30 seconds, 58jC for
20 seconds, and then 72jC for 50 seconds, for 28 cycles.
The risk of genomic DNA yielding a product was pre-
vented by designing primers that bridged intronic se-
quences. Glyceraldehyde-3-phosphate dehydrogenase
(G3PDH) gene was used as an endogenous control. G3PDH
primer sequences were 5V-ACC ACA GTC CAT GCC ATC
AC-3V and 5V-TCCACCACCCTGTTGCTGTA-3V. Reactions
in which pure water replaced RNA were used as RT-PCR–
negative controls. Visualization of target bands on a 0.8%
agarose gel with ethidium bromide staining was performed to
determine the expression of mRNA transcripts.
Follow-up
Follow-up survey was obtained from 37 lung cancer
patients every 3 to 6 months after operation. All patients
were checked by chest X-ray, computed tomography, and
others to confirm if there was any metastasis and/or recur-
rence. The average follow-up period was 24 months (range
19–30 months).
Statistical Analysis
Statistical significance was determined by SPSS 11.0 for
windows. Chi-square test was performed for multiple com-
parisons among individual samples, and significant differ-
ence was defined as P < .05.
Results
Prediction of a Putative Tumor-Specific Gene from the
Analysis of Human Chromosome 8q24
The DNA sequence of the q24 region of human chromo-
some 8 was obtained from the Human Genome Resource.
Unknown coding regions in the DNA sequence were ob-
tained by analysis of Genemark, an online tool used to pre-
dict coding regions in a DNA sequence. All potential coding
regions were analyzed by BLAST programs for human
expressed sequence tag (EST), Unigene, and virtual North-
ern blot analysis in the National Center for Biological Infor-
mation server. In our analysis, when all potential coding
regions located in chromosome 8q24 had been obtained,
four criteria were used to screen the candidates for tumor-
specific genes: first, there must be EST fragments represent-
ing candidate coding regions, and these candidate coding
regions must be transcribed in vivo; second, these EST frag-
ments must be cloned from libraries of either the tumor or
the testis, implying that these EST fragments may be inside
tumor-specific gene sequences; third, if there exist SAGE
tags for sequences of the candidate coding regions, only
the tags absolutely corresponding to the candidate gene
should be selected because there are many SAGE tags
that are homologous to the candidate genes but represent
other genes; fourth, the candidate coding regions must rep-
resent the genes that have not yet been recorded as tumor-
associated genes. When these four criteria are applied,
a potential coding region is found and considered to be
the most promising candidate for tumor-specific gene. In the
Unigene database, there were 18 ESTs representing the
coding region, all of which were derived from the libraries of
different histologic types of cancers, including lung cancer,
colon carcinoma, and pancreatic carcinoma. But there were
no ESTs found in the libraries of normal colon or pancreas.
In the virtual Northern blot analysis, one SAGE tag (AGCA-
GAACCG) representing the coding region was identified. We
found that five SAGE libraries in the database contained at
least one copy of this tag, including pancreatic cancer, ovary
cancer, mesothelioma, and breast cancer cell line MCF7
SAGE libraries. We have proposed this coding region to be a
potential tumor-specific gene and named it asBJ-TSA-9 (Gen-
Bank accession no. AF497803).
Full-Length cDNA Cloning of BJ-TSA-9 and Its
Sequence Analysis
Based on the potential coding region obtained from
genomic DNA sequence analysis, BJ-TSA-9 was assembled
and extended by searching the human EST database. Gene-
specific primers were designed, and the PCR products
were sequenced to confirm the extended sequence. The
sequence of BJ-TSA-9 could not be further extended by
RACE PCR. The 5V untranslated sequence of BJ-TSA-9 con-
tained a stop codon in each of the three possible translational
frames. Exon– intron boundaries were identified by com-
paring the genomic sequence with the full-length cDNA
sequence. All sequences at exon–intron junctions are con-
sistent with the AG–GT rule. Gene structure is shown in
Figure 1, which comprises five exons with a full length of
1936 bp. Its ORF of 1101 bp encompasses parts of exons 1
and 5 and the full length of exons 2, 3, and 4. This gene en-
codes a protein of 367-amino-acid residues. The mRNA of
BJ-TSA-9 is in good agreement with the size observed in
Northern blot analysis (Figure 2).
Expression of BJ-TSA-9 in Normal and Cancer Tissues
For the detection of BJ-TSA-9 expression, 16 different
normal tissues, including the brain, heart, kidney, liver, lung,
Table 1. Sequences of PCR Primers for Detecting the Three Marker Genes.
Gene Sequence of Primers Product
(bp)
BJ-TSA-9 Outer: B1, 5V-CACTTCTTGGAGGTGCCCTGCACG-3V;
B2, 5V-TAGAGGCAGCCAACAAGCGTG-3V
1421
Inner: B3, 5V-CACTTTGGTTCCTGATGGCTT-3V;
B4, 5V-CTCCCAAGCCCAGCTTTCCAAAGG-3V
564
SCC Outer: S1, 5V-GCCCACCTCTGCTTCCTCTA-3V;
S2, 5V-GCTTCTGCTCCCTCCTCTGT-3V
1083
Inner: S3, 5V-GCAAATGCTCCAGAAGAAAG-3V;
S4, 5V-CGAGGCAAAATGAAAAGATG-3V
261
LUNX Outer: L1, 5V-GGGCCTCATTGTCTTCTACGGG-3V;
L2, 5V-GAAGGGTGCAGTCACCAAGGAC-3V
534
Inner: L3, 5V-CTCATTGTCTTCTACGGCTGTTAG-3V;
L4, 5V-CTTTATGCCGAGAGGGATGGT-3V
396
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pancreas, placenta, skeletal muscle, colon, peripheral blood
leukocyte, prostate, small intestine, spleen, testis, and thymus,
were tested by RT-PCR. BJ-TSA-9 mRNA transcript was un-
detectable in all these normal tissues tested (Figure 3A).
The mRNA expression of BJ-TSA-9 was analyzed in the
samples of lung cancer tissues and other cancer tissues. The
BJ-TSA-9 mRNA transcript was expressed in 21 of 40 lung
cancer samples (52.5%) (Figure 3B), 4 of 12 colon cancer
samples (33.3%), and 3 of 10 gastric cancer tissues (30.0%)
(data not shown), but was not detected in surrounding
noncancerous tissues. We further analyzed the frequency
of BJ-TSA-9 expression in different pathological types of
lung cancer, and the expression rate was much higher in
adenocarcinoma (68.8%) than in other types of lung cancer
(squamous epithelial carcinoma, 47.1%; large cell lung can-
cer, 33.3%; small cell lung cancer, 25%). In the assessment
for the expression of BJ-TSA-9 mRNA in eight cancer cell
lines available in our laboratory, including the lung adeno-
carcinoma (A549 and PAa), hepatocellular carcinoma (Bel-
7402, Bel-7405, HLE, and HepG2), leukemia (Jurkat), and
melanoma (Mel-kenny) cell lines, the BJ-TSA-9 mRNA was
detected in lung adenocarcinoma (PAa) only. There was no
positive BJ-TSA-9 signal detected in the cDNA samples
of eight tumor cell lines (melanoma, lung, breast, pancreas,
colon, prostate, and ovary cell lines) purchased from Clon-
tech Laboratories, Inc. (data not shown).
Detection of Disseminated Tumor Cells in the Peripheral
Blood of Lung Cancer Patients
Due to the high detection rate of BJ-TSA-9 in lung cancer
tissues, we wondered whether it could be a biomarker of lung
cancer metastasis. Then, nested RT-PCR was performed to
detect disseminated tumor cells in the peripheral blood of
lung cancer patients. The overall positive detection rate of
BJ-TSA-9 transcript in PBMCs was 34.3% (24 of 70). Taking
into account the positive detection rate (52.5%) of BJ-TSA-9
mRNA in lung cancer, the relative positive frequency of
PBMC samples should be corrected to 65.3%, as only the
lung cancer that expresses BJ-TSA-9 mRNA can be de-
tected in PBMCs. BJ-TSA-9 transcript was undetectable in
the PBMC samples of 20 healthy controls.
We further analyzed the association of clinicopathologi-
cal variables with BJ-TSA-9 transcript expression in the
Figure 1. Genomic structure of BJ-TSA-9 gene and its derived cDNA. BJ-TSA-9 comprises five exons. Exons are depicted schematically as boxes, and introns are
depicted as lines with relative sizes. The number in the boxes indicates the exon number. The full-length cDNA and the ORF of BJ-TSA-9 are shown beneath the
genomic structure.
Figure 2. Northern blot analysis of BJ-TSA-9 expression in lung cancer
tissues and paired noncancerous tissues. G3PDH was used to monitor the
quality of the RNA samples. Ca., cancerous tissues; Adj., adjacent non-
cancerous tissues.
Figure 3. The expression of the BJ-TSA-9 mRNA transcript in normal tissues
and lung cancer samples. The assay was performed by RT-PCR. (A) BJ-
TSA-9 mRNA was not expressed in any normal tissue. M, molecular maker;
P, PAa (lung adenocarcinoma cell line); (1) brain; (2) heart; (3) kidney; (4)
liver; (5) lung; (6) pancreas; (7) skeletal muscle; (8) placenta; (9) ovary; (10)
thymus; (11) prostate; (12) spleen; (13) testis; (14) small intestine; (15) colon;
and (16) leukocytes. (B) Expression of BJ-TSA-9 mRNA in representative
lung cancer tissues and paired adjacent noncancerous tissues. G3PDH was
used to monitor the quality of the RNA sample. Ca., cancerous tissues; Adj.,
adjacent noncancerous tissues.
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peripheral blood of lung cancer patients. BJ-TSA-9 showed
different detection rates for different histologic types of
lung cancer; the positive detection rate was relatively high
in adenocarcinomas (53.6%; 15 of 28) and low in squamous
epithelial carcinoma (23.3%; 7 of 30), large cell lung cancer
(20.0%; 1 of 5), and small cell lung cancer (14.3%; 1 of 7)
(Table 2). Of note, the positive detection rate of BJ-TSA-9
correlated with the progression of clinical stages, being 24.3%
for stages I and II, 39.1% for stage III, and 60.0% for stage IV.
There was no statistically significant association found be-
tween BJ-TSA-9 expression and gender, as well as tumor
differentiation states.
Detection of Circulating Cancer Cells with Multiple Genes
In the attempt to increase the positive detection rate of
circulating cancer cells in lung cancer patients, two additional
known biomarkers of lung cancer (SCC and LUNX), together
with BJ-TSA-9, were also detected in the PBMC samples
of lung cancer patients (Figure 4). Among 70 lung cancer
patients, the positive detection rate of SCC and LUNX in
PBMCs was 32.9% and 40.0%, respectively. With the com-
bination of transcripts of the two tumor markers (BJ-TSA-9 +
LUNX ), the detection rate of circulating tumor cells in-
creased to 62.9%; however, with the combination of three
tumor markers (BJ-TSA-9 + LUNX + SCC), the detection rate
of circulating tumor cells increased to 81.4% (Figure 5).
Therefore, the positive detection rate was dramatically in-
creased with the combination of the three tumor marker gene
transcripts for detection. In the control assays, all these three
gene transcripts were undetectable in the PBMC samples
from healthy controls.
Follow-up
To investigate the relationship between the detection
of circulating tumor cells and the clinical outcome of lung
cancer patients, a follow-up study was performed for an
average of 24 months (range 19–30 months) in 37 patients
after surgical removal of the tumor mass. Four patients with
persistent detection of the three tumor marker transcripts
(BJ-TSA-9, LUNX, and SCC) in PBMCs had recurrence and/
or metastasis. Among these four patients, one died during
this period. In another group of five patients with persistent
detection of two markers, two had recurrence and/or metas-
tasis. In contrast, 21 patients with transient detection of one
tumor marker and seven patients without detection of any
tumor marker all went into remission. The follow-up range
and clinical data of all 37 patients are shown in Table 3.
Discussion
The unveiling of the sequence of human genome makes
bioinformatics an important tool for discovering novel genes.
It is well known that oncogenic retroviruses can cause
cancers in various species. Human endogenous retroviruses
(HERVs) are remnants of ancient retroviral infections that
became fixed in the germ line DNA millions of years ago.
Figure 4. Detection of marker genes in circulating cancer cells of lung cancer patients. The assay was performed by nested RT-PCR. Lanes 1–8: peripheral blood
samples of eight lung cancer patients; lanes 9–10: peripheral blood samples of two healthy volunteers. G3PDH was used to monitor the quality of the RNA samples.
Table 2. Clinicopathological Characteristics and BJ-TSA-9 Expression in
Circulating Cancer Cells of 70 Lung Cancer Patients.
Factors Evaluated n Positive (n) Positive Detection Rate
Pathology
Squ 30 7 7/30 (23.3%)
Ade 28 15 15/28 (53.6%)
LCLC 5 1 1/5 (20.0%)
SCLC 7 1 1/7 (14.3%)
Clinical stages
I and II 37 9 9/37 (24.3%)
III 23 9 9/23 (39.1%)
IV 10 6 6/10 (60.0%)
Tumor differentiation
Good 19 6 6/19 (31.6%)
Moderate 28 11 11/28 (39.3%)
Poor 23 7 7/23 (30.4%)
Sex
Male 14 5 5/14 (35.7%)
Female 56 19 19/56 (33.9%)
Total 70 24 24/70 (34.3%)
Squ, squamous epithelial carcinoma; Ade, adenocarcinoma; LCLC, large cell
lung cancer; SCLC, small cell lung cancer.
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HERVs can potentially affect the expression of adjacent genes
by insertion, recombination, and transcriptional/translational
effects mediated by control elements in long terminal repeats.
As there are some integration sites of HERV in the region
of chromosome 8q24, we assumed that the integration of
HERV might activate some tumor-specific genes, so that
we have analyzed all the potential coding regions located in
chromosome 8q24, including known and unknown genes.
We identified a novel tumor-specific gene, named BJ-TSA-9,
whose mRNA expression is strictly limited to cancer tissues
and is not expressed in any normal tissue. For its specific ex-
pression pattern, BJ-TSA-9may have potential as a biomarker
candidate for cancer.
Lung cancer is a very common and aggressive malig-
nancy. Difficulty in early diagnosis and its propensity to metas-
tasize or relapse result in the poor 5-year survival rate of
lung cancer patients. One of the major causes of recurrence
is metastasis of disseminated tumor cells through the blood
circulation. The number of circulating tumor cells is so small
such that they cannot be detected by conventional diagnostic
methods, such as imaging studies and assays for serum
marker detection. Recently, RT-PCR amplification of target
DNA sequences in the peripheral blood has been increasing
applied for the detection of micrometastases of cancer cells.
This technology may have three advantages for cancer pa-
tients [10]: 1) detection of occult tumor cells at a very early
stage [14]; 2) more efficient analysis of ways to monitor the
efficacy of therapy [24]; and 3) prediction of the kinds of pa-
tients who may have favorable outcomes following removal/
treatment of the primary lesion [32]. In this study, we have
applied it in the detection of micrometastasis in lung cancer
patients during the postoperative period.
CEA, cytokeratin, and preproGRP are the markers most
frequently used to detect circulating tumor cells in the periph-
eral blood of lung cancer patients. However, the high false-
positive detection rate in healthy controls is not satisfactory
[25,33]. Aberrant transcription or contamination makes it un-
reliable for these markers to specifically detect disseminated
cancer cells in the blood of lung cancer patients [24–26].
Thus, molecular markers with strict expression in cancers
are preferred for the detection of disseminated cancer cells.
BJ-TSA-9 is a tumor-specific gene and is highly expressed
in lung cancer. We herein applied BJ-TSA-9 to detect circulat-
ing cancer cells by nested RT-PCR in lung cancer patients.
The positive detection rate of circulating cancer cells was
34.3% (24 of 70) and 53.6% (15 of 28) in the peripheral blood
of patients with various types of lung cancers and lung adeno-
carcinomas, respectively. As the BJ-TSA-9 transcript was un-
detectable in the peripheral blood of 20 healthy donors and
because there was no nonregulated transcription, BJ-TSA-9
seemed fit as a biomarker of circulating lung cancer cells.
Further analysis on the correlation of clinicopathological
variables with BJ-TSA-9 transcript expression in the pe-
ripheral blood of lung cancer patients showed that BJ-TSA-9
was more sensitive to detecting adenocarcinoma (53.6%
positive) than other types (14.3–23.3% positive) of lung
cancer. Early hematogenous metastasis is a prominent char-
acteristic of lung adenocarcinoma, and its prognosis is poor.
Therefore, the application of BJ-TSA-9 is of significant value
in the early detection of micrometastasis for lung adenocarci-
noma patients.
Figure 5. Analysis of positive detection rates using different numbers of
marker genes. The circulating lung cancer cells were detected by one, two, or
three tumor markers using nested RT-PCR. The positive detection rates were
correlated with the increase in the number of marker genes assessed.
Table 3. Follow-up Study in 37 Lung Cancer Patients: PCR Results of Tumor Marker Genes and Clinical Progression.
Metastasis Follow-up A/D Site of PCR Result of Three Marker Genes (Case/Pathological Type)
and/or Relapse (months) Metastasis
L+B+S+ L+S+ L+B+ S+B+ L+ S+ B+ LBS
No 19–20 A 1/Squ 1/Ade 1/Ade 1/Ade
21–22 A 1/Squ 4/Squ 2/Ade 3/Squ
2/Ade 1/SCLC
23–24 A 1/Squ 1/Squ 1/Squ 1/Ade
2/Ade
25–26 A 1/Squ 1/Squ
27–28 A 1/Squ 1/Ade 2/Ade
29–30 A 1/Squ 1/Squ
Yes 23 A Relapse 1/Squ
24 A Liver 1/SCLC
21 A Liver 1/Ade
24 A Liver 1/Squ
25 A Bone 1/Ade
26 D Bone 1/Ade
Squ, squamous epithelial carcinoma; Ade, adenocarcinoma; SCLC, small cell lung cancer; B, BJ-TSA-9; S, SCC; L, LUNX; A, alive; D, dead.
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To increase the detection rate, we have chosen two ad-
ditional known genes, SCC and LUNX, together with BJ-
TSA-9, to detect circulating lung cancer cells. As shown in
Figure 5, the detection rate of circulating lung cancer cells
increased to 62.9% using two tumor markers, and to 81.4%
using three tumor markers. With the combination of the
three tumor markers, the detection of circulating lung adeno-
carcinoma cells also increased to 71.4%. Therefore, detec-
tion by nested RT-PCR assay of the presence of circulating
cancer cells through the application of the three tumor
markers, in combination with conventional Tumor–Node–
Metastasis classification, may lead to early diagnosis and
corresponding therapeutic modalities in patients with lung
cancer, especially in patients with adenocarcinoma.
Moreover, the prognosis of lung cancer patients may be
precisely predicted by the detection of circulating tumor cells
using three the tumor markers described. The prognosis was
extremely poor in patients with three tumor markers detected
in the blood, was relatively poor in patients with two tumor
markers detected in the blood, and could not be determined
in patients with only one tumormarker detected in the blood. In
our 24-month follow-up survey, therewas no recurrenceand/or
metastasis in the lung cancer patients with one tumor marker
detected in the blood or in those without tumor markers. To
confirm the validity of our study, more patients and long-term
follow-up surveys should be carried out.
In conclusion, BJ-TSA-9 is a novel tumor-specific gene
that is highly expressed in human lung adenocarcinoma.
Detection of BJ-TSA-9, SCC, and LUNX transcripts in the
peripheral blood by nested RT-PCR is a sensitive tool for
monitoring disseminated cancer cells, and such detection
may lead to early diagnosis of the recurrence and/or metas-
tasis of lung cancer.
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